In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses
about
In vivo correction of ZAP-70 immunodeficiency by intrathymic gene transferIn situ transduction of stromal cells and thymocytes upon intrathymic injection of lentiviral vectorsRecent Advances in Lentiviral Vaccines for HIV-1 InfectionProtective Antiviral Immunity Conferred by a Nonintegrative Lentiviral Vector-Based VaccineSeparating lentiviral vector injection and induction of gene expression in time, does not prevent an immune response to rtTA in ratsNonintegrating lentiviral vectors can effectively deliver ovalbumin antigen for induction of antitumor immunity.Mucosal immunization with integrase-defective lentiviral vectors protects against influenza virus challenge in micePotent induction of B- and T-cell immunity against human carcinoembryonic antigen-expressing tumors in human carcinoembryonic antigen transgenic mice mediated by direct lentivector injection.HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7.Virus-receptor mediated transduction of dendritic cells by lentiviruses enveloped with glycoproteins derived from Semliki Forest virusA strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation.A nonintegrative lentiviral vector-based vaccine provides long-term sterile protection against malariaDendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in miceImmunization delivered by lentiviral vectors for cancer and infectious diseases.Production of lentiviral vectors with enhanced efficiency to target dendritic cells by attenuating mannosidase activity of mammalian cells.Conventional dendritic cells are required for the activation of helper-dependent CD8 T cell responses to a model antigen after cutaneous vaccination with lentiviral vectors.Diminished Memory T-Cell Expansion Due to Delayed Kinetics of Antigen Expression by Lentivectors.Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization.Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice.Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice.Lentiviral transduction of dendritic cells confers protective antiviral immunity in vivoLentivector prime and vaccinia virus vector boost generate high-quality CD8 memory T cells and prevent autochthonous mouse melanoma.Human fetal liver cells for regulated ex vivo erythropoietin gene therapy.Immunoglobulin Fc fragment tagging allows strong activation of endogenous CD4 T cells to reshape the tumor milieu and enhance the antitumor effect of lentivector immunization.A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responsesDevelopment of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells.Treatment of pulmonary metastatic tumors in mice using lentiviral vector-engineered stem cells.IL10 released by a new inflammation-regulated lentiviral system efficiently attenuates zymosan-induced arthritisEngineered lentivector targeting of dendritic cells for in vivo immunization.Induction of T cell immunity by cutaneous genetic immunization with recombinant lentivectorLocal administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunizationLentivirus as a potent and mechanistically distinct vector for genetic immunizationRecombinant lentivector as a genetic immunization vehicle for antitumor immunity.LV305, a dendritic cell-targeting integration-deficient ZVex(TM)-based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response.HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells.Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification.Emerging applications of lentiviral vectors in dendritic cell-based immunotherapy.Targeting lentiviral vectors for cancer immunotherapy.Lentiviral vectors for cancer immunotherapy and clinical applications
P2860
Q24532255-B15F0A33-1EAB-4677-9175-44944C0D331AQ24805129-F908E85C-B021-44DD-AFD4-769A04CB3209Q26742169-202471AE-CB1B-472D-AD04-7E5CC8104BC6Q27487498-594CD21A-38B5-49BA-83F6-806D1DD14CC8Q33550771-E1216729-AD4A-45F6-B9FF-A818AE505B27Q33564383-FDA4924B-60DC-42F3-88D5-E2A43F8F489AQ33604567-F4B99613-FF8C-45DA-8EB0-C331D8413B58Q33756770-190F89BA-6D20-4C5B-A58E-90F710897C1FQ33877397-E255884B-84F7-4188-A44D-0E056FEF78D6Q33954953-A82D3C01-2225-4735-BAAD-223F05166541Q34330865-F35C0B6A-9160-4F36-A886-C71C5AA3D9CCQ34469817-30F3B298-03DE-415D-A1F5-54615A53E723Q34472125-823A307F-5C0F-4510-88EA-4AA2B59A434AQ34539879-19D5B262-14BA-488A-840A-D684C858DFD9Q34576498-5A25B524-01E0-4745-BCF3-5055B11922A1Q34767725-D3D19A28-B614-4EC1-A46D-93E0946111EAQ34792987-7EAE2955-2CEA-4E09-BFD2-7A85E324BAEAQ34801021-D4E415CF-2C4A-4DDD-8D2E-8ACDDC59A04AQ34801069-68D15D36-D2B8-4224-AE27-A8088D5A3457Q34801323-FFB429C5-C8D7-4E4D-A131-5DED9C558F2CQ34958663-285F1386-D622-43D7-B682-E368D1679E6EQ35122548-A55415B7-E394-4B1A-870A-C975017D00F9Q35147489-E0CB5B89-F5D1-4112-97B2-DC4096052F3BQ35184160-0B2487C9-4362-4EE3-AEFC-C5EAE353BDDDQ35982675-596C700D-9E74-4FAE-A476-E95DAE1403B0Q35990046-F81CBAF9-7322-4D36-9162-B369006C2C40Q36460535-7DF776ED-28B2-4A59-98A6-A4DBE61F3B21Q36482614-40E12BEC-B2F4-4A64-ACE4-0E09008FEC5FQ36512506-C49244AF-17ED-4080-BDD3-21323D5ECBC1Q36629181-744D762E-2666-4698-86AD-0606EF49A8F6Q36751598-487E0554-AD21-47FC-9A34-229A888DA0BBQ36863949-417B26E3-DD1B-4DAE-AF4F-0CEDC6AFECE5Q36969195-16FF72B5-D35B-424F-B79C-CE036082BF63Q37123441-502A522D-089B-4D86-8C10-79927B178DC3Q37225212-96B3FA65-493F-4D4B-84B7-8F9011A2E147Q37422657-EC4FC4B8-7ABF-4DEF-A164-71B46ED13BF4Q37621566-6E53302A-838C-4BA4-800A-B04911E3FA14Q37793233-F194F8B4-DCE3-45E8-9514-5C7764441DE6Q38043924-AEE445AF-0B01-40A4-9341-D380030580DBQ38147100-F0C60994-4029-4DE8-8E46-920596ADA099
P2860
In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
In vivo administration of a le ...... icient CD8(+) T cell responses
@ast
In vivo administration of a le ...... icient CD8(+) T cell responses
@en
type
label
In vivo administration of a le ...... icient CD8(+) T cell responses
@ast
In vivo administration of a le ...... icient CD8(+) T cell responses
@en
prefLabel
In vivo administration of a le ...... icient CD8(+) T cell responses
@ast
In vivo administration of a le ...... icient CD8(+) T cell responses
@en
P2093
P2860
P356
P1476
In vivo administration of a le ...... icient CD8(+) T cell responses
@en
P2093
Christoph Esslinger
Daniela Finke
Frédéric Lévy
H Robson MacDonald
Isabelle Miconnet
Laurence Chapatte
Philippe Guillaume
P2860
P304
P356
10.1172/JCI200317098
P407
P577
2003-06-01T00:00:00Z